NCT02823496 is a NA clinical trial of Sunscreen Lotion , BAY 987521 in Sunscreening Agents, sponsored by Bayer.

Who is sponsoring NCT02823496?

NCT02823496 is sponsored by Bayer.

What drugs are being tested in NCT02823496?

Interventions in NCT02823496: Sunscreen Lotion , BAY 987521, Untreated skin.

What condition does NCT02823496 study?

NCT02823496 studies Sunscreening Agents.

Is NCT02823496 still recruiting?

NCT02823496 is currently completed. Last updated 1 July 2016.

Last reviewed 2016-07-01 · How we verify

NCT02823496

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Human Photoallergy Test

Completed NA Last updated 1 July 2016

What this trial tests

NA trial testing Sunscreen Lotion , BAY 987521 in Sunscreening Agents in 60 participants. Completed in 1 November 2015.

Timeline

1 November 2015

Primary endpoint
1 November 2015

1 November 2015

Quick facts

Lead sponsor	Bayer
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Enrollment	60
Start date	1 November 2015
Primary completion	1 November 2015
Estimated completion	1 November 2015
Sites	1 location across United States

Drugs / interventions tested

Sunscreen Lotion , BAY 987521
Untreated skin

Conditions studied

Sunscreening Agents — all drugs for Sunscreening Agents →

Sponsor

Bayer — full company profile →

Who can join

Adults 18 to 60, any sex, with Sunscreening Agents. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Intensity of skin reactions is evaluated by 5 point scale
Time frame: Up to 72 hours

Sponsor's own description

To evaluate the potential of a test material to produce a photoallergic response.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02823496 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 1 July 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02823496.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing